BUZZ-CoStar to acquire Vexcel for approximately 730 million dollars, stock price drops
路透社2026/10/27 20:56October 27 - ** Real estate data platform CoStar (CSGP.O) saw its share price fall 12% in after-hours trading to $28.30 after announcing the $730 million acquisition of Vexcel Group
** Vexcel is an operator of survey-grade aerial imagery projects
** According to data compiled by London Stock Exchange Group (LSEG), CoStar reported adjusted earnings per share for the third quarter of $0.38, above the market expectation of $0.34
** Third quarter revenue was $952 million, higher than the expected $946.2 million
** Adjusted earnings per share for fiscal year 2026 are expected to be between $1.38 and $1.41
** The median target price given by 22 brokerages covering the stock is $35—LSEG compiled data
** As of Monday's close, CSGP is down about 50% year-to-date
(To facilitate non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of this text and provides it solely for the convenience of readers. Reuters accepts no liability for any harm or loss associated with the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.
After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.
Crypto prices
More
